Cytokinetics (NASDAQ:CYTK) Stock: Insider Robert Blum Sells 7,500 Shares

Cytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert Blum sold 7,500 shares of the firm’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $62.88, for a total value of $471,600.00. Following the completion of the transaction, the chief executive officer owned 278,544 shares of the company’s stock, valued at $17,514,846.72. The trade was a 2.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cytokinetics Stock Performance

NASDAQ:CYTK opened at $63.43 on Thursday. The stock’s 50-day simple moving average is $70.83 and its 200 day simple moving average is $73.27. The company has a market cap of $7.89 billion, a P/E ratio of -8.79 and a beta of 0.41. Cytokinetics, Incorporated has a 52-week low of $54.30 and a 52-week high of $88.31.

Cytokinetics (NASDAQ:CYTK) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.63) by $0.13. The company had revenue of $28.62 million for the quarter, compared to the consensus estimate of $17.59 million. During the same quarter in the previous year, the company posted ($1.12) EPS. The business’s revenue was down 57.1% on a year-over-year basis. As a group, equities analysts predict that Cytokinetics, Incorporated will post -5.98 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cytokinetics

Institutional investors have recently made changes to their positions in the company. Sanders Morris Harris LLC bought a new position in Cytokinetics during the third quarter worth about $1,549,000. Mirador Capital Partners LP raised its stake in Cytokinetics by 3.2% in the 3rd quarter. Mirador Capital Partners LP now owns 208,896 shares of the biopharmaceutical company’s stock worth $13,768,000 after purchasing an additional 6,526 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Cytokinetics by 8.6% in the 3rd quarter. GAMMA Investing LLC now owns 2,700 shares of the biopharmaceutical company’s stock valued at $178,000 after purchasing an additional 213 shares during the period. Cim Investment Management Inc. boosted its holdings in Cytokinetics by 20.9% in the 2nd quarter. Cim Investment Management Inc. now owns 5,657 shares of the biopharmaceutical company’s stock valued at $482,000 after purchasing an additional 979 shares during the period. Finally, Tidal Investments LLC boosted its holdings in Cytokinetics by 24.7% in the 2nd quarter. Tidal Investments LLC now owns 24,921 shares of the biopharmaceutical company’s stock valued at $2,123,000 after purchasing an additional 4,938 shares during the period.

Analysts Set New Price Targets

Several research firms have recently commented on CYTK. Citigroup reissued a “market outperform” rating on shares of Cytokinetics in a report on Friday, August 7th. Morgan Stanley raised shares of Cytokinetics from an “overweight” rating to a “buy” rating in a research note on Tuesday, September 1st. Mizuho boosted their target price on shares of Cytokinetics from $100.00 to $118.00 and gave the stock an “outperform” rating in a report on Wednesday, June 24th. Citizens Jmp upped their price target on shares of Cytokinetics from $105.00 to $110.00 and gave the stock a “market outperform” rating in a research report on Friday, August 7th. Finally, Royal Bank Of Canada upped their price target on shares of Cytokinetics from $112.00 to $113.00 and gave the stock an “outperform” rating in a research report on Thursday, October 8th. Eighteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $105.44.

Cytokinetics News Summary

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: New analyses from the Phase 3 ACACIA-HCM study showed aficamten improved exercise-capacity measures and benefited multiple responder groups in patients with non-obstructive hypertrophic cardiomyopathy. The results also supported the drug’s dose-adjustment strategy and safety profile, potentially strengthening its regulatory and commercial prospects. ACACIA-HCM additional data
• Positive Sentiment: Market coverage has renewed attention on Cytokinetics’ heart-drug pipeline, with commentary suggesting aficamten’s multi-domain benefits could improve the company’s long-term growth and valuation potential. Analysts maintain a broadly favorable view, with 18 Buy ratings, one Hold and one Sell, and an average price target of $106.06—well above recent trading levels. Analyst price target coverage
• Neutral Sentiment: Chief Executive Officer Robert Blum sold 7,500 shares for approximately $471,600 under a pre-arranged Rule 10b5-1 trading plan. He retained 278,544 shares, so the transaction represents only a 2.62% reduction in his direct holdings and is a limited signal of management sentiment. SEC Form 4 filing
• Negative Sentiment: Cytokinetics remains unprofitable, with analysts expecting a full-year loss of approximately $5.98 per share. Recent quarterly revenue also declined year over year, leaving investors focused on the timing of aficamten’s potential approval and commercialization.

Cytokinetics Company Profile

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that improve muscle function. The company applies muscle biology and molecular pharmacology to develop therapies for cardiovascular and neuromuscular diseases in which impaired muscle performance contributes to disease progression or disability.

Its lead programs include aficamten, a next-generation cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy, and other investigational compounds designed to modulate the activity of cardiac or skeletal muscle.